NCT01456273

Brief Summary

This study aims to evaluate, in patients with functional dyspepsia, a model example of medical care based upon the biopsychosocial model (called: the therapeutic encounter) compared with standard medical care based upon the biomedical model (called: medical consultation).

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Mar 2009

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2009

Completed
2.5 years until next milestone

First Submitted

Initial submission to the registry

August 23, 2011

Completed
2 months until next milestone

First Posted

Study publicly available on registry

October 20, 2011

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2011

Completed
Last Updated

October 20, 2011

Status Verified

October 1, 2011

Enrollment Period

2.8 years

First QC Date

August 23, 2011

Last Update Submit

October 19, 2011

Conditions

Keywords

biopsychosocial modelbiomedical modelfunctional dyspepsia

Outcome Measures

Primary Outcomes (1)

  • Score of dyspeptic symptoms questionnaire administered at the beginning and end of treatment.

    between four to six months of treatment

Study Arms (4)

A2- Medical consultation + placebo

PLACEBO COMPARATOR

Traditional medical interview + placebo

Procedure: Traditional Medical Consultation

B1 - Therapeutic Encounter / Omeprazol

ACTIVE COMPARATOR
Procedure: Therapeutic Encounter

B2 - Therapeutic Encounter / Placebo

PLACEBO COMPARATOR
Procedure: Therapeutic Encounter

A1- Medical consultation + omeprazole

ACTIVE COMPARATOR

Traditional medical interview + omeprazole

Procedure: Traditional Medical Consultation

Interventions

Group A will be divided into 2 subgroups : A1- Traditional medical consultation + placebo, and A2- traditional medical consultation plus omeprazole

A1- Medical consultation + omeprazoleA2- Medical consultation + placebo

Group B (who receive care "Therapeutic Encounter") will be divided in subgroup B1, which will receive the "Drug Therapy Classic" and 2 in group B who received placebo.

B1 - Therapeutic Encounter / OmeprazolB2 - Therapeutic Encounter / Placebo

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Clinical diagnosis of functional dyspepsia (according to the Rome II criteria)
  • They must be literate so they can read and fill out the questionnaire and a diary of symptoms without the aid of others

You may not qualify if:

  • Patients who for any reason: not accepting to participate in research, not having signed an informed consent or not answering the questionnaire, the collection period, for whatever reasons
  • Abuse or dependence on alcohol, tobacco, medications or other drugs (licit or illicit)
  • Diabetes (any type
  • pregnancy or breastfeeding (in any stage of the study)
  • organic diseases or severe metabolic or evolving (heart disease, severe hypertension, infectious diseases)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculdade de Medicina do ABC

Santo André, São Paulo, 09060-870, Brazil

RECRUITING

Study Officials

  • Fernando S Guedes, Master

    Faculdade de Medicina do ABC

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Fernando S Guedes, Master

CONTACT

Wilson R Catapani, Doctoral

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

August 23, 2011

First Posted

October 20, 2011

Study Start

March 1, 2009

Primary Completion

December 1, 2011

Study Completion

December 1, 2011

Last Updated

October 20, 2011

Record last verified: 2011-10

Locations